ArticleEClinicalMedicine2023

A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2.

Khvaramze Shaverdashvili et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.